Professor of Biomedical Sciences and Medicine Associate Director, Academic Programs
Oncology
Dr. Robert A. Figlin, MD
|
|
Give Review
Robert A. Figlin practices Oncology. He received 5 awards: "America's Top Doctors", "Top Doctors:LA Area", "America's Top Doctors for Cancer", "Top Doctors:Southern California" and "Super Doctor". Robert A. Figlin is a published doctor and has 98 publications published. The lastest was: 'The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma.
- Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line suni...
- Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal Cell carcinoma.
- Foxp3+ T Cells Inhibit Antitumor Immune Memory Modulated by mTOR Inhibition.
- Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal Cell carcinoma.
- Programmed death-1 inhibition in renal Cell carcinoma: clinical insights and future directions.
- Ramucirumab in metastatic renal Cell carcinoma: The beginning or the end?
- Efficacy and safety of sunitinib in elderly patients with metastatic renal Cell carcinoma.
- A novel personalized vaccine approach in combination with targeted therapy in advanced renal Cell carcinoma.
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal Cell carcinoma.
- Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal Cell carcinoma.
- Targeting angiogenesis in renal Cell carcinoma.
- Targeting PI3K and mTORC2 in metastatic renal Cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.
- A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal Cell carcinoma models.
- Tivozanib in renal Cell carcinoma.
- Cabazitaxel: More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer?
- Tivozanib : current status and future directions in the treatment of solid Tumors.
- Novel Agents and Approaches for Advanced Renal Cell Carcinoma.
- Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal Cell carcinoma: A retrospective analysis☆
- Systemic therapy in renal Cell carcinoma: advancing paradigms.
- Unraveling the role of hypoxia-inducible factor in renal Cell carcinoma: a biological and therapeutic perspective.
- Hypertension as a biomarker of efficacy in patients with metastatic renal Cell carcinoma treated with sunitinib.
- Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal Cell carcinoma.
- Breaking through a plateau in renal Cell carcinoma therapeutics: development and incorporation of biomarkers.
- Deciphering the antiCancer mechanisms of sunitinib.
- Targeted therapies for non-small cell lung Cancer: an evolving landscape.
- Renal Cell carcinoma therapy in 2010: many options with little comparative data.
- Efficacy and safety of pazopanib in patients with metastatic renal Cell carcinoma.
- Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney Cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
- Anti-angiogenic therapy in renal Cell carcinoma: Alone, in combination, or sequentially.
- Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal Cell carcinoma.
- Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal Cell carcinoma treated with temsirolimus versus interferon-alpha.
- Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal Cell carcinoma.
- NCCN clinical practice guidelines in oncology: testicular Cancer.
- NCCN clinical practice guidelines in oncology: kidney Cancer.
- Novel therapeutics for metastatic renal Cell carcinoma.
- Innovations and challenges in renal Cancer: summary statement from the Third Cambridge Conference.
- Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal Cell carcinoma.
- Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal Cell carcinoma of different tumor histologies.
- The role of targeting mammalian target of rapamycin in lung Cancer.
- Prognostic nomogram for sunitinib in patients with metastatic renal Cell carcinoma.
- Targeted therapies for metastatic renal Cell carcinoma: an overview of toxicity and dosing strategies.
- NCCN Task Force Report: mTOR inhibition in solid Tumors.
- Phase 2 trial of talactoferrin in previously treated patients with metastatic renal Cell carcinoma.
- Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung Cancer is associated with a low baseline matrix metalloproteinase-9 and a decline ...
- Dose and schedule study of panitumumab monotherapy in patients with advanced solid Malignancies.
- Temsirolimus for advanced renal Cell carcinoma.
- Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell Cancer.
- Phase I/II study of vaccination with electrofused allogeneic dendritic Cells/autologous tumor-derived Cells in patients with stage IV renal Cell carcinoma.
- Renal cell Cancer.
- Evolving role of novel targeted agents in renal Cell carcinoma.
- Prognostic impact of tumor size on pT2 renal Cell carcinoma: an international multicenter experience.
- Prognostic relevance of the mTOR pathway in renal Cell carcinoma: implications for molecular patient selection for targeted therapy.
- Expression of CXCR3 on mononuclear Cells and CXCR3 ligands in patients with metastatic renal Cell carcinoma in response to systemic IL-2 therapy.
- Innovations and challenges in renal Cell carcinoma: summary statement from the Second Cambridge Conference.
- Cytoreductive nephrectomy for metastatic renal Cell carcinoma: is it still imperative in the era of targeted therapy?
- Protein expression profiles in renal Cell carcinoma: staging, prognosis, and patient selection for clinical trials.
- Sunitinib versus interferon alfa in metastatic renal-Cell carcinoma.
- p21 is a prognostic marker for renal Cell carcinoma: implications for novel therapeutic approaches.
- Newly approved therapies for RCC and their effect on the standard of care.
- Evolving principles of surgical management and prognostic factors for outcome in renal Cell carcinoma.
- Treatment of patients with metastatic renal cell Cancer: a RAND Appropriateness Panel.
- RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal Cell carcinoma.
- Renal Cell carcinoma: the translation of biology to clinical application.
- Prognostic factors in renal Cell carcinoma.
- Mammalian target of rapamycin inhibitors in renal Cell carcinoma: current status and future applications.
- A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung Cancer.
- Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic ...
- Surveillance strategies for renal Cell carcinoma patients following nephrectomy.
- Tobacco smoking, GSTP1 polymorphism, and bladder Carcinoma.
- Role of molecular markers in the diagnosis and therapy of renal Cell carcinoma.
- The role of CXCR2/CXCR2 ligand biological axis in renal Cell carcinoma.
- Postoperative surveillance protocol for patients with localized and locally advanced renal Cell carcinoma based on a validated prognostic nomogram and risk group strat...
- Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal Cell carcinoma.
- Renal Cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
- Using tumor markers to predict the survival of patients with metastatic renal Cell carcinoma.
- Prognostic value of histologic subtypes in renal Cell carcinoma: a multicenter experience.
- G250: a carbonic anhydrase IX monoclonal antibody.
- Surveillance following radical or partial nephrectomy for renal Cell carcinoma.
- Symptoms as well as tumor size provide prognostic information on patients with localized renal Tumors.
- Innovations and challenges in renal Cancer: consensus statement from the first international conference.
- Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal Cell carcinoma therapy.
- Cystic renal Cell carcinoma: biology and clinical behavior.
- Use of the University of California Los Angeles integrated staging system to predict survival in renal Cell carcinoma: an international multicenter study.
- Using protein expressions to predict survival in clear Cell renal carcinoma.
- Safety and efficacy of partial nephrectomy for all T1 Tumors based on an international multicenter experience.
- Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear Cell carcinoma.
- Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate Cancer.
- Cachexia-like symptoms predict a worse prognosis in localized t1 renal Cell carcinoma.
- Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal Cell carc...
- Metastatic renal Cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment.
- Epithelial Cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal Cell carcinoma.
- Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
- Generation of kidney Cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9.
- Prognostic significance of venous thrombus in renal Cell carcinoma. Are renal vein and inferior vena cava involvement different?
- Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal Cell carcinoma: a stratification tool for prospective clini...
- Validation of an integrated staging system toward improved prognostication of patients with localized renal Cell carcinoma in an international population.
Schools
Medical College of Pennsylvania
Cedars Sinai Med Center
UCLA Center Health Science
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Access Plus Savenet
- Basic PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Golden Rule
- Medicare MCR
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Top Doctors:LA Area
- America's Top Doctors for Cancer
- Top Doctors:Southern California
- Super Doctor
Education
-
UCLA Medical Center -
Cedars-Sinai Medical Center
Hospital
-
Ronald Reagan UCLA Medical Center -
Cedars-Sinai Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Edward M. Wolin, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald B. Natale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gauri D. Kelekar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James R. Berenson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory P. Sarna, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amir S. Steinberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William M. Audeh, MD
This Doctor is OpenDoctor Recommended.
|